CD88 Antibody (20/70): sc-53786

CD88 Antibody (20/70) is a rat monoclonal IgG2b antibody that detects CD88 in mouse samples through flow cytometry (FCM). CD88, also known as the C5a receptor (C5aR), is a G protein-coupled integral membrane protein that plays a crucial role in the immune response by serving as a receptor for the inflammatory peptide C5a. Anti-CD88 antibody (20/70) is predominantly expressed on various immune cells, including neutrophils, monocytes, macrophages, and mast cells, as well as on epithelial and endothelial cells. The interaction between C5a and CD88 is vital for mediating inflammatory responses, as CD88 triggers the production of acute phase proteins in the liver, which are essential for the body′s defense mechanisms during inflammation. Furthermore, elevated levels of CD88 in the brain have been linked to inflammatory conditions, highlighting CD88′s significance in neuroinflammation. Research has also indicated that the C5a/CD88 pathway may contribute to the pathogenesis of rheumatoid arthritis, and CD88 enhances the responsiveness of human bronchial epithelial cells to C5a when exposed to environmental irritants such as cigarette smoke. CD88 monoclonal antibody (20/70) is an invaluable tool for studying these complex interactions and CD88′s role in various inflammatory diseases.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CD88 Antibody (20/70) References:

1. A key role of C5a/C5aR activation for the development of sepsis.  |  Riedemann, NC., et al. 2003. J Leukoc Biol. 74: 966-70. PMID: 12960283
2. Receptors for complement C5a. The importance of C5aR and the enigmatic role of C5L2.  |  Lee, H., et al. 2008. Immunol Cell Biol. 86: 153-60. PMID: 18227853
3. The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction.  |  Bamberg, CE., et al. 2010. J Biol Chem. 285: 7633-44. PMID: 20044484
4. C5a receptor expression is associated with poor prognosis in urothelial cell carcinoma patients treated with radical cystectomy or nephroureterectomy.  |  Wada, Y., et al. 2016. Oncol Lett. 12: 3995-4000. PMID: 27895761
5. Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.  |  Merkel, PA., et al. 2020. ACR Open Rheumatol. 2: 662-671. PMID: 33128347
6. SAP deficiency aggravates periodontitis possibly via C5a-C5aR signaling-mediated defective macrophage phagocytosis of Porphyromonas gingivalis.  |  Wang, L., et al. 2023. J Adv Res. 50: 55-68. PMID: 36243399
7. Inhibiting C5a/C5aR to treat ANCA-associated vasculitides.  |  Terrier, B. and Karras, A. 2023. Joint Bone Spine. 90: 105472. PMID: 36273796
8. Stiffness-tuned and ROS-sensitive hydrogel incorporating complement C5a receptor antagonist modulates antibacterial activity of macrophages for periodontitis treatment.  |  Gan, Z., et al. 2023. Bioact Mater. 25: 347-359. PMID: 36852104
9. Blockade of C5a receptor unleashes tumor-associated macrophage antitumor response and enhances CXCL9-dependent CD8+ T cell activity.  |  Luan, X., et al. 2024. Mol Ther. 32: 469-489. PMID: 38098230
10. Inhibition of complement factor C5a or C5aR for cholesterol crystal embolism-related vascular thrombosis with microvascular injury and its consequences.  |  Zhao, D., et al. 2024. Kidney Int. 106: 819-825. PMID: 39142565

The preferred CD88 antibody is CD88 Antibody (B-6): sc-271949.